Last reviewed · How we verify
Hiberix TM
Hiberix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier.
Hiberix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier. Used for Prevention of invasive Haemophilus influenzae type b disease in infants and children.
At a glance
| Generic name | Hiberix TM |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Target | Haemophilus influenzae type b polysaccharide capsule (PRP) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified polyribosylribitol phosphate (PRP) polysaccharide from the Hib capsule conjugated to meningococcal outer membrane protein complex (OMPC). This conjugation enhances immunogenicity by converting the polysaccharide into a T-cell-dependent antigen, enabling robust antibody production and immunological memory in vaccinated individuals, particularly in infants and young children.
Approved indications
- Prevention of invasive Haemophilus influenzae type b disease in infants and children
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hiberix TM CI brief — competitive landscape report
- Hiberix TM updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI